These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1. Ngiow SF; Young A; Jacquelot N; Yamazaki T; Enot D; Zitvogel L; Smyth MJ Cancer Res; 2015 Sep; 75(18):3800-11. PubMed ID: 26208901 [TBL] [Abstract][Full Text] [Related]
4. Clinical Significance of Uhercik M; Sanders AJ; Owen S; Davies EL; Sharma AK; Jiang WG; Mokbel K Anticancer Res; 2017 Aug; 37(8):4249-4254. PubMed ID: 28739716 [TBL] [Abstract][Full Text] [Related]
5. PD-1 or PD-L1 Blockade Restores Antitumor Efficacy Following SSX2 Epitope-Modified DNA Vaccine Immunization. Rekoske BT; Smith HA; Olson BM; Maricque BB; McNeel DG Cancer Immunol Res; 2015 Aug; 3(8):946-55. PubMed ID: 26041735 [TBL] [Abstract][Full Text] [Related]
6. Combination cancer immunotherapy and new immunomodulatory targets. Mahoney KM; Rennert PD; Freeman GJ Nat Rev Drug Discov; 2015 Aug; 14(8):561-84. PubMed ID: 26228759 [TBL] [Abstract][Full Text] [Related]
7. Resistance to PD1/PDL1 checkpoint inhibition. O'Donnell JS; Long GV; Scolyer RA; Teng MW; Smyth MJ Cancer Treat Rev; 2017 Jan; 52():71-81. PubMed ID: 27951441 [TBL] [Abstract][Full Text] [Related]
8. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy. McArthur HL; Page DB Clin Adv Hematol Oncol; 2016 Nov; 14(11):922-933. PubMed ID: 27930644 [TBL] [Abstract][Full Text] [Related]
9. Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy. Rojas JJ; Sampath P; Hou W; Thorne SH Clin Cancer Res; 2015 Dec; 21(24):5543-51. PubMed ID: 26187615 [TBL] [Abstract][Full Text] [Related]
10. Programmed Death-1 Ligand-1 (PDL1) Expression Is Associated with the Prognosis of Patients with Stage II/III Gastric Cancer. Tamura T; Ohira M; Tanaka H; Muguruma K; Toyokawa T; Kubo N; Sakurai K; Amano R; Kimura K; Shibutani M; Maeda K; Hirakawa K Anticancer Res; 2015 Oct; 35(10):5369-76. PubMed ID: 26408698 [TBL] [Abstract][Full Text] [Related]
11. Checkpoint inhibitors in bladder and renal cancers: results and perspectives. Aoun F; Kourie HR; Sideris S; Roumeguère T; van Velthoven R; Gil T Immunotherapy; 2015; 7(12):1259-71. PubMed ID: 26595284 [TBL] [Abstract][Full Text] [Related]
12. PDL1-targeted vaccine exhibits potent antitumor activity by simultaneously blocking PD1/PDL1 pathway and activating PDL1-specific immune responses. Tian H; Kang Y; Song X; Xu Y; Chen H; Gong X; Zhang W; Xu Y; Xia X; Gao X; Yao W Cancer Lett; 2020 Apr; 476():170-182. PubMed ID: 32092355 [TBL] [Abstract][Full Text] [Related]
13. A combination of PD‑1/PD‑L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy (Review). Kong X; Lu P; Liu C; Guo Y; Yang Y; Peng Y; Wang F; Bo Z; Dou X; Shi H; Meng J Mol Med Rep; 2021 May; 23(5):. PubMed ID: 33760188 [TBL] [Abstract][Full Text] [Related]
14. HSP70 vaccine in combination with gene therapy with plasmid DNA encoding sPD-1 overcomes immune resistance and suppresses the progression of pulmonary metastatic melanoma. Geng H; Zhang GM; Xiao H; Yuan Y; Li D; Zhang H; Qiu H; He YF; Feng ZH Int J Cancer; 2006 Jun; 118(11):2657-64. PubMed ID: 16425224 [TBL] [Abstract][Full Text] [Related]
15. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises. Massari F; Santoni M; Ciccarese C; Santini D; Alfieri S; Martignoni G; Brunelli M; Piva F; Berardi R; Montironi R; Porta C; Cascinu S; Tortora G Cancer Treat Rev; 2015 Feb; 41(2):114-21. PubMed ID: 25586601 [TBL] [Abstract][Full Text] [Related]
16. Immunotherapy for sarcomas. Nakata E; Fujiwara T; Kunisada T; Ito T; Takihira S; Ozaki T Jpn J Clin Oncol; 2021 Apr; 51(4):523-537. PubMed ID: 33611603 [TBL] [Abstract][Full Text] [Related]
17. Expression and significance of CD47, PD1 and PDL1 in T-cell acute lymphoblastic lymphoma/leukemia. Yang K; Xu J; Liu Q; Li J; Xi Y Pathol Res Pract; 2019 Feb; 215(2):265-271. PubMed ID: 30466764 [TBL] [Abstract][Full Text] [Related]
18. Synergistic effect of programmed cell death protein 1 blockade and secondary lymphoid tissue chemokine in the induction of anti-tumor immunity by a therapeutic cancer vaccine. Moeini S; Saeidi M; Fotouhi F; Mondanizadeh M; Shirian S; Mohebi A; Gorji A; Ghaemi A Arch Virol; 2017 Feb; 162(2):333-346. PubMed ID: 27699512 [TBL] [Abstract][Full Text] [Related]
19. Preclinical evidence that PD1 blockade cooperates with cancer vaccine TEGVAX to elicit regression of established tumors. Fu J; Malm IJ; Kadayakkara DK; Levitsky H; Pardoll D; Kim YJ Cancer Res; 2014 Aug; 74(15):4042-52. PubMed ID: 24812273 [TBL] [Abstract][Full Text] [Related]